A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer
CONCLUSION: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.PMID:38630382 | DOI:10.1007/s10147-024-02517-z (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Katsumasa Nakamura Keiji Nihei Yoshihiro Saito Naoto Shikama Shin-Ei Noda Ryusuke Hara Toshiyuki Imagumbai Takashi Mizowaki Takeshi Akiba Etsuo Kunieda Masanori Someya Saiji Ohga Jiro Kawamori Takuyo Kozuka Yosuke Ota Koji Inaba Takeshi Kodaira Yoshiyuki Source Type: research
Genital Surgery Outcomes Using an Individualized Algorithm for Hormone Management in Transfeminine Individuals
CONCLUSION: An individualized algorithm for preoperative hormone management for TF GS resulted in perioperative continuation of GAHT for the majority of individuals without significantly increasing the risk for post-operative surgical complications while maintaining stable behavioral health measures perioperatively.PMID:38629916 | DOI:10.1210/clinem/dgae269 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 17, 2024 Category: Endocrinology Authors: Justine Herndon Nidhi Gupta Caroline Davidge-Pitts Nicole Imhof Cesar Gonzalez Sara Carlson Marissa Will Jorys Martinez-Jorge Vahe Fahradyan Lily Tamire Anna Lin Todd B Nippoldt Alice Y Chang Source Type: research
Growth and Adult Height Attainment in Danish Transgender Adolescents Treated with GnRH Analog and Sex Hormones
CONCLUSION: The minor reduction in adult height of trans girls after hormone treatment may be beneficial to some, whereas trans boys did not experience height gain.PMID:38627922 | DOI:10.1210/clinem/dgae263 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 17, 2024 Category: Endocrinology Authors: Pernille Badsberg Norup Mette Ewers Haahr Peter Christiansen Lise Aksglaede Line Cleemann Trine Holm Johannsen Anders Juul Katharina M Main Source Type: research
A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer
CONCLUSION: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.PMID:38630382 | DOI:10.1007/s10147-024-02517-z (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Katsumasa Nakamura Keiji Nihei Yoshihiro Saito Naoto Shikama Shin-Ei Noda Ryusuke Hara Toshiyuki Imagumbai Takashi Mizowaki Takeshi Akiba Etsuo Kunieda Masanori Someya Saiji Ohga Jiro Kawamori Takuyo Kozuka Yosuke Ota Koji Inaba Takeshi Kodaira Yoshiyuki Source Type: research
Genital Surgery Outcomes Using an Individualized Algorithm for Hormone Management in Transfeminine Individuals
CONCLUSION: An individualized algorithm for preoperative hormone management for TF GS resulted in perioperative continuation of GAHT for the majority of individuals without significantly increasing the risk for post-operative surgical complications while maintaining stable behavioral health measures perioperatively.PMID:38629916 | DOI:10.1210/clinem/dgae269 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 17, 2024 Category: Endocrinology Authors: Justine Herndon Nidhi Gupta Caroline Davidge-Pitts Nicole Imhof Cesar Gonzalez Sara Carlson Marissa Will Jorys Martinez-Jorge Vahe Fahradyan Lily Tamire Anna Lin Todd B Nippoldt Alice Y Chang Source Type: research
Growth and Adult Height Attainment in Danish Transgender Adolescents Treated with GnRH Analog and Sex Hormones
CONCLUSION: The minor reduction in adult height of trans girls after hormone treatment may be beneficial to some, whereas trans boys did not experience height gain.PMID:38627922 | DOI:10.1210/clinem/dgae263 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 17, 2024 Category: Endocrinology Authors: Pernille Badsberg Norup Mette Ewers Haahr Peter Christiansen Lise Aksglaede Line Cleemann Trine Holm Johannsen Anders Juul Katharina M Main Source Type: research
A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer
ConclusionThe safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - April 17, 2024 Category: Cancer & Oncology Source Type: research
Menopause hormone therapy prescribing in ambulatory care visits among midlife and older U.S. women from 2018 to 2019
Menopause hormone therapy (HT) is indicated for the treatment of vasomotor symptoms of menopause, premature menopause, genitourinary syndrome of menopause, and prevention of osteoporosis [1]. After the 2002 Women's Health Initiative (WHI) study results were published, HT prescribing rates plummeted 66 % amidst fears of cardiovascular disease, venous thromboembolism, and breast cancer [2]. In 2009–2010, the prevalence of HT use was 4.7 %, decreased from 22.4 % in 1999–2000 [3]. Almost no recent studies have reported HT prescribing rates in representative patient samples in the U.S. (Source: Maturitas)
Source: Maturitas - April 17, 2024 Category: Primary Care Authors: Talia H. Sobel, Nadra E. Lisha, Alison J. Huang Tags: Short communication Source Type: research
Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: A conceptual review
The evidence and our beliefs about the beneficial or harmful effects of hormone therapy (HT) on brain aging have changed quite dramatically over time. In the last five years, several observational studies have shown an increased risk of dementia in women who had received HT [1 –5]. However, these results are opposite to the results of several observational studies and some clinical trials published over the last 30 years [6,7]. Therefore, in a 2022 editorial, we suggested that the answer to the simple question: “Is HT protective or harmful for cognitive decline and dementia?” is actually quite complex and may vary ...
Source: Maturitas - April 16, 2024 Category: Primary Care Authors: Walter A. Rocca, Kejal Kantarci, Stephanie S. Faubion Tags: Review article Source Type: research
The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis
ConclusionThe utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced. (Source: Osteoporosis International)
Source: Osteoporosis International - April 15, 2024 Category: Orthopaedics Source Type: research
Chronotype changes after sex hormone use: A prospective cohort study in transgender users of gender-affirming hormones
This study provides the first prospective assessment of sex hormone use and chronotype in transgender persons, showing that GAHT can change chronotype in line with cisgender sex differences. These findings provide a basis for future studies on biological mechanisms and clinical consequences of chronotype changes.PMID:38616311 | DOI:10.1080/07420528.2024.2339989 (Source: Chronobiology International)
Source: Chronobiology International - April 14, 2024 Category: Biology Authors: Margot W L Morssinkhof Annefleur Zwager Karin van der Tuuk Martin den Heijer Ysbrand D van der Werf Dirk Jan Stenvers Birit F P Broekman Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
Hormone therapy in the management of stage four (asymptomatic metastatic) breast cancer in women
Clin Med (Lond). 2023 Nov;23 Suppl 6:60. doi: 10.7861/clinmed.23-6-s60.NO ABSTRACTPMID:38614738 | DOI:10.7861/clinmed.23-6-s60 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Suvam Banerjee Source Type: research
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
J Clin Med. 2024 Mar 24;13(7):1873. doi: 10.3390/jcm13071873.ABSTRACTHormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care o...
Source: Clinical Breast Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Chiara Tommasi Giulia Air ò Fabiana Prattic ò Irene Testi Matilde Corian ò Benedetta Pellegrino Nerina Denaro Laura Demurtas Mariele Dess ì Sara Murgia Giovanni Mura Demi Wekking Mario Scartozzi Antonino Musolino Cinzia Solinas Source Type: research
